SCHEMBL14022013

SCHEMBL14022013

O=C(Nc1ccc(Oc2ccncc2)cc1)Nc1ccc(Cl)c(Cl)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.63
EPHX2 P34913 2/20 0.63
RAF1 P04049 6/20 0.62
LMNA P02545 4/20 0.60
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
HTT P42858 2/20 0.60
NPC1 O15118 1/20 0.60
ADORA3 P0DMS8 1/20 0.60
CHRM1 P11229 1/20 0.60
SLC6A2 P23975 1/20 0.60
PDE4A P27815 1/20 0.60
ADRA1A P35348 1/20 0.60
OPRM1 P35372 1/20 0.60
PDE3A Q14432 1/20 0.60
NLRP3 Q96P20 1/20 0.60
KDR P35968 3/20 0.60
BRAF P15056 1/20 0.60
MAPK14 Q16539 1/20 0.60
TNNI3K Q59H18 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14022019 0.88 RAF1 (0.58) EPHX2RAF1LMNAMEN1KMT2A
SCHEMBL11008724 0.87 EPHX1 (0.81) EPHX1EPHX2RAF1LMNAMEN1
SCHEMBL15574278 0.86 RAB9A (0.62) LMNAHTTNPC1MAPTMAPK1
SCHEMBL936533 0.84 RAF1 (0.73) EPHX2RAF1MEN1KMT2AADORA3
SCHEMBL30462521 0.84 RAF1 (0.73) EPHX2RAF1MEN1KMT2AADORA3
SCHEMBL14022021 0.83 RAF1 (0.56) RAF1LMNAMEN1KMT2AHTT
SCHEMBL29045853 0.82 RAF1 (0.70) EPHX2RAF1MEN1KMT2AADORA3
SCHEMBL14067061 0.81 KDR (0.61) EPHX2RAF1MEN1KMT2ANPC1
SCHEMBL28863218 0.80 CDK8 (0.83) EPHX1EPHX2CA12CA1CA2
SCHEMBL18037977 0.80 LMNA (0.56) EPHX1EPHX2RAF1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269265-A1 Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas MILLER SCOTT 2008-10-30 US disclosed
US-20080269265-A1 Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas MILLER SCOTT 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269265-A1 Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas BRAF, RAF1, MAP2K2 EPHX1 2555/4885EPHX2 1842/4885RAF1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.